CXCL10 As a Biomarker Of ILD in Patients WithRA

Interstitial Lung Disease in Patients With Rheumatoid Arthritis Clinical Trial

Official title:

CXCL10 As a Biomarker Of Interstitial Lung Disease in Patients With Rheumatoid Arthritis

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04356066
• Other study ID #: zahraa
• Status: Not yet recruiting
• Phase: N/A
• Start date: December 19, 2020
• Est. completion date: January 19, 2022

Study information

• Verified date: January 2020
• Source: Assiut University
• Contact: Naima Mohamed Mostafa, professor doctor
• Phone: 01223947372
• Email: naimamohamed21[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Rheumatoid arthritis is a chronic inflammatory disease that affects the joints, causing symmetric pain, stiffness, swelling, and limited motion and function of multiple joints, its fibro inflammatory manifestations may develop in other organs.

Description:

Rheumatoid arthritis is complicated by lung manifestations, such as interstitial lung disease which is the most common cause of morbidity and mortality in rheumatoid arthritis patients. Rheumatoid arthritis-interstitial lung disease is a progressive fibrotic disease of the lung parenchyma that includes a broad spectrum of disorders such as nonspecific interstitial pneumonia, usual interstitial pneumonia , desquamative interstitial pneumonia, cryptogenic organizing pneumonia, diffuse alveolar damage, acute interstitial pneumonia, and lymphocytic interstitial pneumonia . Rheumatoid arthritis-interstitial lung disease in which available data indicate that dysregulated inflammatory cascades can elaborate a host of cytokines, chemokines, and growth factors that collectively promote epithelial and endothelial cell damage, angiogenesis, fibroblast differentiation/proliferation, and lung fibrosis . Given the clinical implications of putative signaling cascades involved in these processes, biomarkers that can be used to clarify disease pathogenesis and identify factors governing disease progression are clearly needed .

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 80
• Est. completion date: January 19, 2022
• Est. primary completion date: January 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Adult rheumatoid arthritis patients who fulfilled the 2010 American College of Rheumatology/European league against rheumatism criteria for the classification of Rheumatoid Arthritis.

2. Adult rheumatoid arthritis patients with interstitial lung disease.

Exclusion Criteria:

1. Individuals with other autoimmune diseases (systemic lupus erythematosus, polyarteritis nodosa, dermatomyositis, scleroderma, spondyloarthritis and inflammatory bowel disease).

2. Individuals with hepatitis, Rhinovirus infection, cerebral malaria.

3. Individuals with colorectal carcinoma, syndrome of frailty, vetiligo.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Interstitial Lung Disease in Patients With Rheumatoid Arthritis
• Lung Diseases
• Lung Diseases, Interstitial

Intervention

Diagnostic Test:
• serum cxcl10 by ELISA
serum sample

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

References & Publications (1)

1. Chen J, Doyle TJ, Liu Y, et al. Biomarkers of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2015;67(1):28-38. doi:10.1002/art.38904 2. Richards TJ, Eggebeen A, Gibson K, et al. Characterization and peripheral blood bio

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CXCL10 As a Biomarker Of Interstitial Lung Disease in Patients With Rheumatoid Arthritis	serum level	2 years